GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Price-to-Owner-Earnings

Pharming Group (CHIX:PHARMA) Price-to-Owner-Earnings

: (As of Today)
View and export this data going back to 2008. Start your Free Trial

As of today (2024-04-19), Pharming Group's share price is €1.047. Pharming Group does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Pharming Group's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Pharming Group was 81.00. The lowest was 13.10. And the median was 24.08.


CHIX:PHARMa's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.62
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-19), Pharming Group's share price is €1.047. Pharming Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.02. Therefore, Pharming Group's PE Ratio for today is At Loss.

As of today (2024-04-19), Pharming Group's share price is €1.047. Pharming Group's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.02. Therefore, Pharming Group's PE Ratio without NRI for today is At Loss.

During the past 13 years, Pharming Group's highest PE Ratio without NRI was 289.33. The lowest was 0.00. And the median was 18.19.


Pharming Group Price-to-Owner-Earnings Historical Data

The historical data trend for Pharming Group's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.23 31.26 35.20 54.80 -

Pharming Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.80 - - - -

Competitive Comparison

For the Biotechnology subindustry, Pharming Group's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, Pharming Group's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pharming Group's Price-to-Owner-Earnings falls into.



Pharming Group Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pharming Group's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.047/-0.03
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharming Group  (CHIX:PHARMa) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Pharming Group Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pharming Group's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group (CHIX:PHARMA) Business Description

Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.

Pharming Group (CHIX:PHARMA) Headlines

No Headlines